MedTrace Logo

Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction

NCT03167216 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-12-18

No results posted yet for this study

Summary

The objective of this study is to evaluate inhibition of mast cells and the histamine 1 receptor (H1R) for treatment of chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS).

Conditions

  • Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Interventions

DRUG

Cromolyn Sodium

Mast cell stabilizer

DRUG

Cetirizine Hydrochloride

Histamine receptor antagonist

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Northwestern University

    lead OTHER

Principal Investigators

  • Praveen Thumbikat, PhD · Northwestern University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2022-04-01
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03167216 on ClinicalTrials.gov